The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography.
In this study, 2-[18F]fluoro-2-deoxy-D-glucose, [( 18F]FDG) was used to radiolabel human granulocytes in vitro for possible clinical use by positron emission tomography (PET). Uptake of [18F]FDG was dependent on the amount of glucose in the labelling medium, e.g. when 1 x 10(7) granulocytes were incubated with [18F]FDG containing 15 micrograms/mL glucose 80% of [18F]FDG was incorporated within 30 min, but in the presence of 1 mg/mL of glucose it was reduced to 2%. Increasing the cell concentration and activating the granulocytes with Streptococcus pneumoniae, opsonized zymosan or phorbol myristate acetate all increased the uptake of [18F]FDG. Retention of the [18F]FDG by the cells as [18F]FDG-6-phosphate was also dependent on the extracellular glucose concentration, 9% was released within 60 min in the absence of glucose, but 27% in the presence of 1 mg/mL glucose.
Osman
S
S
MRC Cyclotron Unit, Hammersmith Hospital, London, England.
Danpure
H J
HJ
D002470:Cell Survival; D002478:Cells, Cultured; D002855:Chromatography, Thin Layer; D003847:Deoxyglucose / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D005462:Fluorine Radioisotopes / Q000378:metabolism / Q000493:pharmacokinetics; D019788:Fluorodeoxyglucose F18; D006098:Granulocytes / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D013268:Stimulation, Chemical; D013296:Streptococcus pneumoniae; D013696:Temperature; D013755:Tetradecanoylphorbol Acetate; D014055:Tomography, Emission-Computed; D015054:Zymosan / Q000494:pharmacology
D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D015054:Zymosan; D003847:Deoxyglucose; D013755:Tetradecanoylphorbol Acetate